Relapsed or Refractory B-cell Lymphoma Clinical Trial
Official title:
Selinexor Combined With R-GDP Regimen for TP53-altered Relapsed/Refractory Diffuse Large B-cell Lymphoma: a Single Arm, Single Center, Phase II Study
To evaluate the efficacy and safety of selinexor combined with R-GDP regimen in the treatment of patients with TP53-altered relapsed or refractory B-cell lymphoma.
This study is a single-arm, open-label exploratory clinical trial. To evaluate the efficacy and safety of selinexor combined with R-GDP regimen in the treatment of patients with TP53-altered relapsed or refractory B-cell lymphoma. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04056975 -
Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma
|
Phase 1 | |
| Recruiting |
NCT05806580 -
Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma
|
Phase 4 | |
| Recruiting |
NCT03208556 -
Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma
|
Phase 1 | |
| Not yet recruiting |
NCT05814848 -
A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma
|
Phase 4 | |
| Recruiting |
NCT03391726 -
CART-19 Cells for R/R B-cell Lymphoma
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04887025 -
Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell Lymphoma
|
Phase 1 | |
| Recruiting |
NCT05720052 -
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06045585 -
JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma
|
Early Phase 1 |